AN2 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AN2 Therapeutics, Inc. (ANTX) on April 9, 2026. The filing discloses the execution of a new Open Market Sale Agreement and the termination of a prior sales agreement.
Key Financial Metrics and Capital Activities
- New Offering Capacity: The Company may issue and sell up to $80 million of common stock under the new agreement with Jefferies LLC.
- Commission Structure: Jefferies will receive a commission of up to 3.0% of gross proceeds from any sales.
- Prior Offering Results: Under the terminated agreement with TD Cowen, the Company sold 2,502,000 shares for aggregate proceeds of $20,016,251.
- Revenue and Profit: The filing text does not provide current revenue, profit, cash flow, or margin data.
- Debt and Liquidity: The filing text does not provide specific debt or liquidity metrics.
Material Changes
The primary material change is the replacement of the Company's equity sales agent. Effective April 9, 2026, AN2 Therapeutics terminated its Sales Agreement with TD Securities (USA) LLC (originally dated April 6, 2023) and entered into a new agreement with Jefferies LLC to facilitate "at the market" offerings.
Outlook, Risks, and Management Commentary
The Company has established a mechanism to raise capital through an "at the market" offering, allowing for flexible sales of shares on the Nasdaq Global Select Market. The offering will terminate upon the sale of all shares or upon ten days' prior written notice by either party. The filing includes customary indemnification rights for the sales agent. No specific forward-looking guidance or risk factors beyond the standard terms of the sales agreement are detailed in this excerpt.
Investor Verification Checklist
- Verify the current share price and market capitalization to assess the potential dilution impact of the $80 million offering capacity.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific pricing parameters and termination conditions.
- Confirm the Company's current cash runway and burn rate to understand the urgency of capital raises.
- Monitor future filings for actual sales volumes and proceeds generated under the new Jefferies agreement.